为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肝细胞癌的过继细胞治疗：临床试验综述
英文原题：Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials.
查看英文原题
Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肝细胞癌（HCC）是最常见的原发性肝癌类型。免疫检查点抑制剂（ICIs）已成为HCC一线治疗的新参考标准，取代了索拉非尼等酪氨酸激酶抑制剂（TKIs）。许多不同联合方案的临床试验已在开发中，以验证用于治疗HCC患者的新型免疫疗法。过继性细胞疗法（ACT），也称为细胞免疫疗法，采用嵌合抗原受体（CAR）或表达新型T细胞受体（TCR）的基因修饰T细胞，可能代表一种有前景的替代方法，通过改造免疫系统以识别肿瘤细胞，从而获得更好的临床结局。在这篇综述中，我们简要讨论了ACT作为HCC中有前景的治疗模式的概况，以及正在进行的临床试验的最新进展。
展开英文摘要原文
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Immune checkpoint inhibitors (ICIs) have become the new reference standard in first-line HCC treatment, replacing tyrosine kinase inhibitors (TKIs) such as sorafenib. Many clinical trials with different combinations are already in development to validate novel immunotherapies for the treatment of patients with HCC.
Adoptive cell therapy (ACT), also known as cellular immunotherapy, with chimeric antigen receptors (CAR) or gene-modified T cells expressing novel T cell receptors (TCR) may represent a promising alternative approach to modify the immune system to recognize tumor cells with better clinical outcomes. In this review, we briefly discuss the overview of ACT as a promising treatment modality in HCC, along with recent updates of ongoing clinical trials.
论文信息
- 作者
- Ozer M、Goksu SY、Akagunduz B、George A、Sahin I
- 第一作者单位
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.United States
- 通讯作者单位
- Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32608, USA.United States
- 期刊
- Cancers2023 Mar 16
- 原文标识
- PubMed 36980692 · DOI 10.3390/cancers15061808
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →